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There are about 300—600 million episodes of clinical Plas-
modium falciparum infections globally every year.1 Malaria
remains a major cause of morbidity and mortality in tropical
countries. Because of the relentless increase in resistance of
malaria parasites to conventional drugs, including chloro-
quine, sulfadoxine—pyrimethamine, and mefloquine, new
therapeutic approaches have been developed. The key one
among these has been artemisinin-based combination ther-
apy (ACT).2,3
The artemisinin group of drugs was discovered in China
from a crude extract of the wormwood plant Artemisia
annua (qinghao).4 Artemisinin is the parent compound thatcan be variedly modified at the C10 position to produce
artesunate, artemether, arteether, dihydroartemisinin, or
artelinic acid. Artesunate is a water-soluble hemisuccinate
derivative of dihydroartemisinin. The hemisuccinate group
in the molecule confers water solubility and relatively high
oral bioavailability. Artesunate is highly active against both
the sexual and asexual forms of the four species of Plas-
modium that affect humans.5 The antimalarial action of
artemisinins has been attributed to their ability to generate
free radicals. The endoperoxide moiety, which is essential
for antimalarial activity, is believed to generate free radi-
cals within the parasites. These free radicals form covalent
bonds with key parasite proteins, such as membrane trans-
porters, thereby impairing their functions.6 However, an
alternative mechanism of action based on inhibition of the
calcium ATPase (sarcoplasmic endoplasmic reticulum cal-
222 Correspondencecium ATPase, SERCA) of the malarial parasites has been
suggested.7
A 29-year-old public servant presented with a 6-hour
history of repetitive, jerky, and involuntary movements of
the body, which started gradually after the second dose of a
brand of oral artesunate. The purposeless spasms were said
to have started in the limbs and later involved the whole
body. He had been having moderate-grade intermittent
fever, headache, and generalized body weakness for three
days and decided to do self-medication for presumptive
malaria fever by using artesunate tablets. There was no neck
pain or rigidity, no photophobia, altered sensorium, weak-
ness of the limb(s), or upper respiratory tract symptoms.
There was no previous or concurrent history of trauma to the
head. He was not on any other medications besides artesu-
nate, and there was no known prior use of artemisinin
derivatives. There was no personal or family history of chorea
or any movement disorders, no history of seizure disorder,
and his hemoglobin genotype was AA.
Physical examination revealed an anxious young man who
was conscious and fully oriented. There was no pallor, jaun-
dice, or cyanosis, and his right axillary temperature was
37.6 8C. There were repetitive, jerky, and uncontrollable
movements of the whole body with spasms mostly affecting
the lower limbs. His cognitive functions were intact. There
were neither facial ticks nor signs of meningeal irritation,
ataxia, or asterixis. All cranial nerves were intact. Muscular
tones, power and tendon reflexes were normal, and sensa-
tions were intact. Other systems were essentially normal.
He was admitted, and blood samples were taken for
malarial parasite blood films, serum electrolytes, BUN and
creatinine, and random plasma glucose assays. The blood
films were positive for malarial parasites, but the serum
electrolytes, BUN, creatinine, and glucose were within nor-
mal limits. Other appropriate investigations were done. He
was reassured and counseled and the offending drug, arte-
sunate, was stopped. Intramuscular diazepam (20 mg) was
administered. The same dose was repeated one hour later
and subsequently followed with oral diazepam 5 mg every
6 hours for the next 48 hours. The patient improved consid-
erably with chorea completely subsided within 24 hours of
admission. He was treated with amodiaquine and sulfadox-
ine—pyrimethamine and discharged after 36 hours. He was
followed up for more than 9months after discharge and there
was no recurrence of chorea.
ACT has become the therapy of choice for malaria in some
African countries following treatment disappointments and
attendant increased ill health, deaths, and enormous eco-
nomic losses associated with chloroquine resistance. The
most commonly reported adverse effects of artemisinins
include transient gastrointestinal disturbance, which may
be a feature of the acute malaria in itself.8 However, neu-
rotoxicity, principally in the form of brain stem lesions, has
been identified in animals receiving high doses over long
periods.9—13 The neurotoxicity included gait disturbances,
loss of spinal and pain response reflexes, loss of brain stem
and eye reflexes, seizure-like activity, and stereotypic move-
ment disorders. Ataxia, slurred speech, tremor, and hearing
loss have also been reported in a small number of humans.14—
19 Toovey and Jamieson15 reported that treatment of uncom-
plicated malaria with co-artemether (artemether—lumefan-
trine) was associated with hearing loss among subjectsworking at a construction site in Mozambique. However,
these neurological effects may not likely be of clinical
significance, particularly because of limited penetration
of artemisinin derivatives into the cerebrospinal fluid.20—
27 Although chorea per se has not been reported in humans
following the use of artemisinin derivatives for malaria,
Brewer et al.9 reported the onset of a clinical neurologic
syndrome with dose-related changes in seizure-like activity
and stereotypic movement disorders in Sprague—Dawley
rats exposed to high doses of artemether and arteether over
long periods. Neurotoxicity appears to be partly mediated
through artemisinin induced oxidative stress in exposed
brainstems.28
Chorea is a neurologic disorder characterized by invo-
luntary spasmodic movements of the body. Movements are
jerky and arrhythmic, and may involve the whole body.
Drugs are one of the recognized causes of chorea. It may
occur as a result of increased dopaminergic activity in the
projections from substantia nigra to the striatum, resulting
in decreased GABAergic activity from the striatum to the
globus pallidus.29,30 Drug treatment of chorea includes:
dopaminergic blockers (e.g., haloperidol), dopaminergic
depletors (e.g., tetrabenazine), benzodiazepines (e.g.,
diazepam), or anticonvulsants (e.g., phenytoin). We used
a benzodiazepine, diazepam, for our patient and the
response was dramatic.
This report is to sensitize health professionals to the
possibility of human neurotoxicity, particularly chorea, with
the use of artemisinin derivatives. It also calls for increased
vigilance for the adverse reactions of these increasingly used
antimalarial drugs. Neurotoxicity should be evaluated parti-
cularly in children, as the susceptibility of the developing
nervous system to injury could be greater than in adults.
There is urgent need to develop the next generation of
artemisinins with reduced toxicity, increased potency, and
improved stability.
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doi:10.1016/j.ijid.2007.06.015Kytococcus schroeteri, a rare agent of endocar-
ditis
We report herein the case of a prosthetic valve endocarditis
due to Kytococcus schroeteri.
A 70-year-old man with a bioprosthetic valve was
admitted to Laveran Hospital in Marseilles, France in Sep-
tember 2004 with a fever (39 8C), headache, and cough.
Blood cultures were sterile. He was treated with vancomycin
and gentamicin for four weeks. We were unable to recover
any further details about this period.
In March 2005 he was admitted to Timone Hospital in
Marseilles for a new episode of fever and shivers. On admis-
sion, his white blood cell count was 11.53  109/l (80.8%
polymorphonuclear cells), his hemoglobin level was 13.1 g/dl, the erythrocyte sedimentation rate was 24 mm in the first
hour, and his C-reactive protein level was 83 mg/l. Transe-
sophageal echocardiography showed a 4-mm vegetation on
the aortic bioprosthetic valve and an intertrigonal abscess
(Figure 1). Computed tomography examination showed an
embolic cerebral stroke and bilateral renal emboli.
An endocarditis diagnostic kit was performed, as pre-
viously described.1 The first blood culture of the kit was
performed using a set of Bactec1 Plus Aerobic/F and Bactec1
Lytic/10 Anaerobic/F bottles (BD Diagnostic Systems, Sparks,
MD, USA). The specimen volume is 10 ml for each bottle. The
second and third blood cultures of the kit were collected in
Bactec Plus Aerobic/F bottles, with 2-h intervals between
samples. Blood bottles were incubated for 5 days at 37 8C
under continuous automated monitoring for bacterial growth
in the medium. One blood culture grew Gram-positive cocci.
